首页>投融资
Bicara Therapeutics
上市
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.In March 2023, BIn icara Therapeutics completed an oversubscribed $108 million Series B financing
基本信息
-
公司全称Bicara Therapeutics Inc
-
类型生物制剂开发商
-
产业领域药品研发/制造、生物药、医药研发/制造
-
公司人数15~50人
-
地址116 Huntington Avenue Suite 703 Boston MA 02116
-
联系电话1-617-4684219
-
邮箱info@bicara.com
-
成立时间2020-01-01
投融资
-
2024-09-13上市3.15亿美元未透露
-
2023-12-12C轮1.65亿美元BraidwellThe Rise FundTPG Life Sciences InnovationsDeerfieldFairmountAisling Capital
-
2023-03-06B轮1.08亿美元InvusEight Roads VenturesOmega FundsRA CapitalJanus Henderson InvestorsF-Prime CapitalBioqube VenturesPremjiInvestAcorn BioventuresRed Tree Venture Capital
-
2021-03-15未透露4000万美元未透露
- 加载更多
相关投融资企业
上市
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.In March 2023, BIn icara Therapeutics completed an oversubscribed $108 million Series B financing
上市后再融资
Cullinan Oncology是一家外部癌症治疗药物的开发商，如果早期研究表明它不起作用，该药物将迅速终止一项药物计划。该公司的治疗药物是通过内部实验室或外部通过商业、学术和制药合作获得的资产开发的，从而使研究人员能够获得具有独特，经济高效的商业模式的高度多样化的肿瘤治疗药物组合。
C轮
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.In March 2023, BIn icara Therapeutics completed an oversubscribed $108 million Series B financing
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息